linezolid Issue Section: BRIEF REPORTS The increase in the incidence of drug-resistant gram-positive pathogens has created a great challenge in the treatment of
Conclusions: The real-life frequency of new-onset of thrombocytopenia in patients receiving linezolid for a minimum of 5 days was 17
The primary endpoint of this study was the recovery time of platelets, which was dened as the time from the rst day of thrombocytopenia until a platelet count of > 100,000 cells/ul
An exposure-response relationship has been clarified for thrombocytopenia and previous studies showed that linezolid trough concentration ( Cmin) values above
This hematologic adverse effect resolved within nine days after linezolid cessation (day 19)
The use of LZD > 7 days during the course of myelosuppression and the low level of albumin can prolong the time required for platelet count increase and recovery
Introduction Thrombocytopenia is the most common adverse effect of linezolid treatment
If patients switched extended gram-positive therapy, they were included in the LZD group as long as they had received ≥ 72 hours of linezolid
Univariate and multiple logistic regression analyses were performed to identify the risk factors of linezolid-related severe thrombocytopenia
The incidence and risk factors of LIT in neonatal patients were possibly different from other populations based on pathophysiological characteristics
PDF | Rationale: Thrombocytopenia caused by linezolid (LZD) is common, with a reported prevalence as high as 11
Severe anemia and thrombocytopenia were defined as ≥ grade 3 adverse events according to the NIAID Division of Microbiology and Infectious Disease Adult Toxicity table
The secondary endpoint was the time required for platelet count increase, which was dened as the time from the rst day of thrombocytopenia until the rst day of a per - Introduction Linezolid and vancomycin have an important place among therapeutic antimicrobial options for multidrug-resistant gram-positive infections
The overall incidence of thrombocytopenia was 20
Thrombocytopenia is an adverse effect reported with both and can lead to treatment interruption
2002 Aug 1;35(3):348-9
Using data from the Food and Drug Administration adverse event reporting system (July
Many of the cytotoxic drugs used for cancer chemotherapy and other conditions produce dose-dependent reductions in platelet counts due to bone marrow suppression as a known effect of the drug
Based on this Purpose The incidence of linezolid-induced thrombocytopenia (LIT) has been reported to vary widely across studies
Significant predictive factors for thrombocytopenia included the duration of linezolid therapy longer than or equal to 7 days (adjusted odds Linezolid is an oxazolidinone class antibiotic that is used for serious or problematic infections caused by resistant enterococcal or staphylococcal organisms